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ABSTRACT 
Blood pressure (BP) is the hydrostatic force exerted by the blood pushing against the 
wall of blood vessels as it is pumped by the heart. Hypertension is a chronic progressive 
disorder in which BP is persistently increased above the considered normal values. This 
medical condition represents a major risk factor for cardiovascular disease as well as for 
renal events. It is estimated that hypertension affects one billion people globally, 
accounting for 9.4 million deaths each year. The aetiology of hypertension is the result 
of a complex interaction between environmental and pathological factors affecting 
different systems, along with genetic predisposition. Accurate blood pressure readings 
are essential for its proper diagnosis and treatment. Lifestyle modifications, including 
healthy dietary patterns and regular physical activity, play a key role in the prevention 
of hypertension. The Mediterranean diet has been reported to exert health benefits 
such as reduced chronic diseases incidence and longer life expectancy. These beneficial 
effects have been attributed, in part, to olive oil consumption. The olive tree (Olea 
europaea L.), a typical tree crop from the Mediterranean Basis, has been used in 
traditional medicine since antient times for its biological and pharmacological 
properties. In this review, preclinical studies and nutritional interventions in humans 
assessing the effects of bioactive compounds of Olea europaea L. on BP with potent use 
in the prevention or treatment of hypertension, have been summarized.  
RESUM 
La pressió arterial és la força hidrostàtica exercida per la sang contra la paret dels vasos 
sanguinis a mesura que és bombejada pel cor. La hipertensió és una malaltia crònica i 
progressiva en què hi ha un augment persistent de la pressió arterial. Aquesta condició 
mèdica representa un factor de risc important de patir malaltia cardiovascular així com 
malalties renals. S’estima que la hipertensió afecta a un bilió de persones a nivell 
mundial, sent responsable de 9,4 milions de morts cada any. L’etiologia de la hipertensió 
és el resultat de la complexa interacció entre factors ambientals i fisiopatològics, 
juntament amb la predisposició genètica de cada individu. Fer mesures precises de la 
pressió arterial és essencial a l’hora de diagnosticar la hipertensió i establir un 
tractament. Els hàbits de vida, dins dels quals s’inclouen els hàbits alimentaris, són 
factors modificables que poden prevenir la hipertensió. La dieta mediterrània s’ha 
associat a efectes beneficiosos per la salut com és la reducció de la pressió arterial i el 
seu conseqüent risc cardiovascular. Aquests beneficis s’atribueixen bàsicament al 
consum de l’oli d’oliva. L’olivera (Olea europaea L.), un arbre de cultiu típic de la conca 
mediterrània, ha estat utilitzada en la medicina tradicional des de l’antiguitat per les 
seves propietats biològiques i farmacològiques. En aquesta revisió, es recullen estudis 
preclínics i intervencions nutricionals en humans que mostren compostos bioactius 
d’Olea europaea L. amb efecte sobre la pressió arterial i amb ús potencial en la prevenció 
i tractament de la hipertensió. 
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1.  INTRODUCTION  
Blood pressure (BP) is regulated by different physiological systems that modify blood 
flow and the vascular resistance of blood vessels of organs. Therefore, any mechanism 
that contributes to the imbalance of BP levels, is a potential target for the development 
of high blood pressure (1). 
Hypertension is a clinical condition characterized by a persistent rise in BP. It is one of 
the major risk factors for cardiovascular disease (CVD) and causes functional alterations 
in the wall of blood vessels and in target organs such as the brain, heart and kidneys. 
Hypertension is known as the “silent killer”, since it remains asymptomatic for years 
until it reaches advanced stages, when heart attack or stroke may occur. Stage 1 of 
hypertension is considered when systolic BP (SBP) and diastolic BP (DBP) are ≥140 mmHg 
and ≥90 mmHg, respectively. Periodic monitoring of BP is of high importance for the 
earliest possible diagnosis of hypertension and the prevention of its subsequent clinical 
complications (1–3).  
The Global Burden Disease Study performed in 2015, demonstrated that hypertension 
kills an estimated 9.4 million people annually and is considered one of the leading 
preventable causes of premature mortality worldwide (1,4,5). The increasing prevalence 
of hypertension is not correlated with income level and becomes more common with 
population ageing, sedentarism and body weight gain. Most patients suffer from 
essential hypertension, in which the cause cannot be determined, leading to non-
specific treatments (1,2). 
However, hypertension can be prevented with lifestyle modifications, beginning with 
changes in dietary patterns. Epidemiological studies as well as nutritional interventions 
in humans have reported that the Mediterranean diet (MedDiet) has beneficial effects 
on hypertension and prevents the risk of CVD. MedDiet is based in vegetables, fresh 
fruit, whole grains, legumes, nuts, fish, olive oil and a moderate intake of alcohol, 
especially red wine. It has been observed that people adopting MedDiet have lower BP 
levels, improvement of lipid profile as well as better endothelial function and, in general, 
longer life expectancy (6).  
The olive tree, Olea europaea L., is a widely distributed species found mainly in the 
Mediterranean region. It is generally used to produce olive oil, one of the most 
representative components in the MedDiet. Olive oil consumption has been attributed 
to pharmacological activities, as it is considered a source of valuable bioactive 
compounds. Its chemical composition is involved in the maintenance of the physiological 
state and in the prevention of chronic diseases associated with oxidative stress like 
cancer, inflammation, metabolic alterations, atherosclerosis and CVD. Although most 
olive fruits are intended for the production of olive oil, several of them are processed 
into table olives. Table olives are one of the most representative fermented foods in the 
MedDiet containing a non-nutritional fraction with interesting biological properties. 
Olive leaves have been used in Mediterranean folk medicine since ancient times, as they 
are rich in important bioactive compounds, chiefly polyphenols (7). 
Objectives & Integration of the fields of study 
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Given that medicinal plant derivatives have shown similar efficacy and tolerability to 
conventional drugs for the treatment of hypertension and, due to the hypotensive effect 
observed in the products of Olea europaea L. (7,8), several experimental studies have 
been carried out with the intention of evaluating its bioactive compounds including 
polyphenols, secoiridoid phenols, flavonoids, pentacyclic triterpenes, oleic acid and fatty 
acids with antihypertensive activity.  
2. OBJECTIVES  
Hypertension is among the main risk factors of CVD. Despite the availability of 
conventional medicines, by 2015 it was estimated that one out of four adults suffered 
from hypertension (1). Side effects of current antihypertensive drugs and poor 
accessibility to pharmacological treatment, can be some of the causes of this high 
mortality. However, risk of hypertension can be prevented. For these reasons, the 
current study aims to develop the following objectives:  
i. Define BP and its regulatory systems in the human body 
ii. Explain how BP is measured in the clinical setting and stress the importance of 
its regular control  
iii. Describe hypertension with its epidemiology, aetiology, clinical manifestations 
and complications, pathogenesis, diagnostic and treatment strategies  
iv. Analyse potential non-pharmacological therapeutic strategies to prevent and 
treat hypertension 
v. Assess the importance of the Mediterranean-style diet in the prevention of 
hypertension  
vi. Highlight the presence Olea europaea L. plant and its derivative products in the 
MedDiet 
vii. Identify the bioactive compounds of Olea europaea L. with BP-lowering 
properties 
viii. Draw conclusions from the stated objectives  
3. INTEGRATION OF THE FIELDS OF STUDY 
As main areas of study, this review integrates the field of physiology and 
physiopathology, as well as nutrition and bromatology and pharmacognosy, all of them 
studied in the Pharmacy degree.  
The principal field of study is physiology and pathophysiology since first part covers the 
physiology of blood pressure in the human body, followed by the explanation of 
physiopathology of hypertension. Firstly, the present work defines the medical 
condition and how the disease develops, describing its causes, clinical manifestations 
and complications, pathological mechanisms, diagnostic methods and treatment 
options. 
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In the second place, the scope of nutrition and bromatology takes part, as the MedDiet 
is considered as one of the most potent therapeutic keys for the prevention and control 
of high blood pressure. In addition, the focus is directed more towards the beneficial 
effects of using Olea europaea L. and its derivative products to combat the progression 
of hypertension.  
The integration of pharmacognosy field in this work should be also taken into account 
since the major purpose is to identify which natural substances from Olea europaea L. 
have therapeutic properties to prevent and treat hypertension.  
4. MATERIAL AND METHODS  
In order to reach the objectives of the present study, a literature review was carried out 
through primary and secondary bibliographical sources present in PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) and Scopus (https://www.scopus.com/) 
electronic databases. In addition, books of human physiology and pathophysiology and 
international guidelines for the management of high blood pressure were consulted.  
The research looked for experimental preclinical studies and clinical trials assessing the 
effects of Olea europaea L. bioactive compounds on BP. Journal articles and scientific 
reviews were found using keywords relating to Olea europaea L.: “Olea europaea L.” OR 
“olive leaves” OR “olive oil” OR “olive tables” OR “Olea europaea L. compounds” OR 
“oleic acid” OR “pentacyclic triterpenes” OR “oleanic acid” OR polyphenols OR 
hydoxytyrosol OR flavonoids OR oleuropein, in combination with the terms of: “blood 
pressure” OR hypertension OR “high blood pressure”. 
When selecting articles, their quality, publication date and focus on Olea europaea L. 
and its effects on blood pressure were taken into account. Furthermore, references from 
extracted articles and recent reviews were examined in order to identify significant 
additional publications and complete data collection.  
The study selection considered in vivo, in vitro and clinical trials in the English language. 
Research literature includes references dating from 1983 to 2019.  
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5. RESULTS AND DISCUSSION  
5.1. BLOOD PRESSURE 
BP is the hydrostatic pressure that exerts blood on the wall of the blood vessels when 
the heart contracts, expressed in mmHg (9). This force pushes blood through the entire 
vascular system, which is divided in two circuits: the systemic and pulmonary circulation 
(10,11). 
The term systole refers to the period of contraction of the left ventricle (LV) of the heart, 
while the relaxed state is called diastole. The balance between systole and diastole 
determines an individual’s BP (9).  
The SBP is the maximum value of arterial pressure and the DBP corresponds to the 
minimum value. In optimal conditions, SBP is lower than 120 mmHg and DBP lower than 
80 mmHg. The difference between SBP and DBP is known as pulse pressure (9–11).   
Regarding BP, the vascular system can be divided in two parts: high-pressure part, which 
extends from the LV to the systemic capillaries, and the low-pressure part, which 
extends from the systemic capillaries to the right ventricle (RV), passes through the 
pulmonary circulation and reaches de LV in its relaxation phase (11). 
Therefore, as blood leaves the aorta arteria and flows through the systemic circulation, 
BP decreases progressively. Approximately, it drops about 35 mmHg as blood moves 
from the systemic arteries to the systemic arterioles and capillaries. When blood flow 
reaches the RV, BP has dropped to 0 mmHg. This pressure gradient is what allows blood 
to circulate and the greater it is, the greater the blood flow (9–11). 
The mean arterial pressure (MAP) is not the arithmetic mean of SBP and DBP, since SBP 
has longer duration than DBP. Instead, it is the area beneath the curve that determines 
the pressure in a cardiac cycle divided by the duration of the cycle. The value of the MAP 
in a large systemic artery is around 95 mmHg (11).  
To understand BP, classical hemodynamic laws are applied to blood circulation. The 
most used is analogous to Ohm’s Electricity Law: ∆𝑃 = 𝐹 × 𝑅, where ∆𝑃 is the pressure 
difference between two points (P1 and P2), F is the blood flow and R is the vascular 
resistance between these two pressure points (3). This relation can be used for the 
whole circulation with the equation: 𝑀𝐴𝑃 = 𝐶𝑂 × 𝑃𝑉𝑅, where CO is the cardiac output 
and RVP the total peripheral vascular resistance (12).  
The CO is the blood flow ejected by the heart. It is the product of the heart rate (HR), 
which is the number of heartbeats per minute, and the stroke volume (SV), which is the 
output of each heartbeat. The PVR is the total resistance to blood flow through 
peripheral vascular bed. Hence, a BP elevation may be the result of an increase in PVR, 
CO or a combination of both (11,12).  
Vascular resistance is determined by the size of the lumen of blood vessels, the smaller 
the diameter is, the greater the resistance to blood flow; by blood viscosity, which occurs 
Results and discussion 
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when the number of red blood cells in plasma is high; and total blood vessel length, 
which is proportional to the resistance to blood flow (10).  
The major factors that determine BP are the total blood volume, heart rate (HR), the 
elastic properties of blood vessels, CO and the PVR. The homeostasis of BP aims to 
assure constant blood flow in vital organs such as the brain, heart and kidneys (10).  
 
Figure 1. Major factors involved in the rise in blood pressure, adapted from (10). 
5.1.1. Regulation of blood pressure 
5.1.1.1. Short term regulation mechanisms 
There are several systems to maintain blood pressure relatively constant in the body. 
The short-term regulation mechanisms allow to cope with sudden imbalances of blood 
pressure, such as those that occur when changing the body position, on a time scale of 
seconds or minutes (10).   
Neural Regulation 
The cardiovascular center (CVC) is a region of the human brain located in the medulla 
oblongata which can regulate blood pressure. It modulates the activity of the autonomic 
nervous system (ANS) on the heart and blood vessels diameter. The neurons scattered 
within CVC form the cardiostimulatory center, the cardioinhibitor center and the 
vasomotor center (9,10). 
The cardiostimulator center stimulates the cardiac activity by transmitting sympathetic 
nerve impulses to the heart and to the blood vessels through the spinal cord. The 
cardioinhibitor center, on the contrary, slows down cardiac function via 
parasympathetic nerve impulses to the heart conveyed along the vagus (X) nerves. 
Therefore, the sympathetic nervous system (SNS) and the parasympathetic nervous 
system (PNS), influence the heart rate and the contractility of the heart in an opposite 
way (9,10). 
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The vasomotor center controls the blood vessels diameter by causing vasoconstriction 
or vasodilation. This region of the CVC continuously generates nerve impulses that 
propagate along sympathetic neurons to smooth muscle of blood vessels walls. Thus, 
sympathetic stimulation leads to constriction of arteries, arterioles and most veins. 
Consequently, the peripheral vascular resistance increases, which translates into higher 
blood pressure (9,10).  
a. Baroreflex: baroreceptors are mechanoreceptors located at strategic pressure 
sites as the carotid sinus, the aortic arch and the wall of the atrias. They are 
stimulated when there is a distention of blood vessels due to an elevation of BP. 
Immediately, the sensory information is sent to the CVC and as a result BP 
returns to normal levels. This negative feedback system is called baroreflex (11).  
b. Chemoreflex: chemoreceptors are specialised sensory receptor cells. The carotid 
bodies and the aortic bodies are peripheral chemoreceptors, whose location is 
close to the baroreceptors. Central chemoreceptors, on the other hand, are 
situated in the medulla. They sense chemical changes in the body environment 
such as low arterial PO2, high arterial PCO2  and a decrease of blood pH, due to a 
BP decrease. Their activation leads to sympathetic nerves stimulation and, as a 
final result, to an increase of BP (11). 
 
5.1.1.2. Long term regulation mechanisms 
In addition to short-term regulation mechanisms, long-term regulatory systems act 
more slowly, on a time scale of hours or days. In this case, blood volume is regulated 
through blood vessels and kidneys, which control the volume of extracellular fluid (11).  
a. Renin-angiotensin-aldosterone system (RAAS) 
The RAAS has wide effects in the regulation of BP. This system is present in many organs, 
but mostly in the kidney, where it has the main part to regulate pressure-volume 
homeostasis (1,9).  
The liver secretes angiotensinogen into the blood. When a drop in BP occurs, the kidney 
releases renin, which is an enzyme that converts angiotensinogen to angiotensin I (ANG 
I). Renin releasement is induced by various stimuli, among them, decreased renal 
afferent arteriolar perfusion pressure, activation of renal sympathetic nerves and 
several vasodilators, e.g. prostaglandin E2 (1).  
Thanks to angiotensin-converting enzyme (ACE), ANG I is transformed into angiotensin 
II (ANG II), especially on the lung endothelial cells (1,11). ANG II is a powerful 
vasoconstrictor peptide and plays a key role increasing BP when significant blood loss 
occurs, during exercise and in other situations affecting renal blood flow. Under normal 
conditions, ANG II is not present in plasma in necessary concentrations to produce 
vasoconstriction. However, when the perfusion pressure of the kidney decreases, renin 
is released and, consequently, plasma levels of ANG II increase causing intense 
vasoconstriction in the renal circulation (11).  
Results and discussion 
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ANG II has other effects that rise MAP in an indirect way. When activates the angiotensin 
type 1 receptor (AT1), ANG II triggers myocardial contractility, stimulates thirst sensation 
and reduces renal flow by enhancing sodium reabsorption and promoting the secretion 
of aldosterone (1,11). Aldosterone is a steroid hormone released into blood from the 
adrenal cortex. When aldosterone binds to its mineralocorticoid receptor, it causes 
sodium reabsorption and potassium excretion. Indirectly, this influences water 
retention, thus increasing blood volume and BP (1). 
On the other hand, when ANG II stimulates the angiotensin II type receptor (AT2), the 
effects are the opposite, leading to vasodilation, natriuresis and antiproliferative effects 
(1). In the figure below (Figure 2), RAAS mechanisms involved in BP regulation are 
represented.  
 
Figure 2. The role of Renin Angiotensin Aldosterone System (RAAS) in the regulation of blood 
pressure, adapted from (1). 
ACE, Angiotensin-Converting Enzyme; PVR, Peripheral Vascular Resistance 
 
b. Vasopressin (AVP)  
When there is a reduction of blood volume, the osmotic pressure of the extracellular 
fluid raises. This fact activates the pituitary gland, which releases AVP. This hormone, 
also called antidiuretic hormone, binds to V1a receptors on vascular smooth muscle cells 
(VSMCs). On the one hand, it increases water reabsorption in the kidney tubules of the 
nephron, and, on the other hand, it raises BP by increasing PVR (11).  
c. Natriuretic peptides  
Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP) have important 
natriuretic and vasodilatory properties, which allow a balance between sodium and BP. 
They are released from atrial and ventricular cells, respectively, in response to atrial or 
ventricular stretch after administration of a sodium load (1).  
Results and discussion 
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ANP and BNP increase glomerular filtration rate and inhibit sodium reabsorption. This 
leads to systemic vasodilation, reduction in blood volume and, therefore, decrease in 
BP. Simultaneously, natriuretic peptides have indirect effects such as the inhibition of 
renin, aldosterone and AVP release (1,11).  
 
d. Endothelium  
The endothelium of blood vessels produces vasoactive substances, including nitric oxide 
(NO), which is the most important in the regulation of BP. NO is released by 
endothelium cells because of flow-induced shear stress and leads to vascular smooth 
muscle relaxation, thus resulting in vasodilation and increase of blood flow. Endothelin 
1 (ET1) is another substance secreted by endothelial cells. ET1 exerts a powerful 
vasoconstrictive action when it binds to its receptor (ETA). The balance between NO 
and ET1, along with other vasoregulatory factors, determine final the endothelial tone 
(1). 
 
Figure 3. Main neuroendocrine systems regulating blood pressure, adapted from (1). 
BP, Blood Pressure; RAAS, Renin Angiotensin Aldosterone System; SNS, Sympathetic Nervous System 
 
5.1.2. Measurement of blood pressure  
The device used in clinical measurement of BP is a sphygmomanometer. A manual 
sphygmomanometer consists on an inextensible cuff containing an inflatable bag which 
is wrapped around the arm. The clinician inflates the cuff by a rubber squeeze-bulb to a 
pressure higher than the expected SBP level to occlude the brachial artery and stop the 
blood flow. Then the pressure in the cuff, measured by means of mercury, is slowly 
released. In the auscultatory method, the doctor uses a stethoscope to detect the 
Korotkoff sounds on the brachial artery. This method allows both SBP and DBP to be 
determined (11). 
A pressure of approximately 120 mmHg has to be applied to close blood vessels in young 
healthy people. When the brachial artery is closed, the physician cannot hear any sound. 
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The time when the SBP is reached corresponds to the first tapping sound, due to 
turbulent blood flow. The character of Korotkoff sounds changes as cuff pressure 
decreases towards DBP level, becoming cushioned and softened. Finally, the sound 
disappears as the artery is completely open and blood returns to a laminar flow (11).  
At present, the preferred method in physician’s offices to measured BP is using 
semiautomatic or automatic sphygmomanometers. The BP is initially measured in both 
upper arms using the proper cuff size according to the patient’s arm circumference. The 
inadequate BP office measurement can lead to errors in the classification of patient’s BP 
and, consequently, poorly indicated treatments (2).  
In 2005, the American Heart Association (AHA) published guidelines for BP reading in 
the doctor’s office. These recommendations related to the adequate position and 
posture of the patient, the adequate placement of the BP cuff, the rate of deflation of 
the sphygmomanometer mercury column as well as advices for patients to be seated in 
a comfortable and unstimulated way for 5 minutes before the first measurement (2,13). 
For patients who monitor their BP at home, the AHA recommends resting in a chair with 
the cuff properly placed during 3-5 minutes before taking any readings. Three different 
readings have to be taken with, at least 1 minute apart. However, the European Society 
of Hypertension guidelines says that two readings should be taken after a 5-minute wait. 
For office measurement, the AHA recommends a minimum of two reading since BP has 
constant variations and a single measurement is less accurate rather than two or three 
measurements. Moreover, the third reading often results in lower BP values than the 
first, implying the reclassification of the patient’s hypertension state (13).  
Hence, to properly control hypertension, accuracy in BP readings and adherence to 
measurement guidelines are crucial.  
 
5.2. HYPERTENSION 
5.2.1. Definition and prevalence of hypertension 
Hypertension is defined as a persistent increase in BP above normal considered values, 
whether in SBP, DBP or both (9). Further definition would be the level of BP in which the 
benefits of the treatment, either based on drugs or lifestyle modifications, outweigh its 
risks (14). 
Hypertension is among the most common worldwide chronic diseases found in humans, 
especially in the Western world (14). In 2015, the global prevalence of hypertension was 
estimated at 1.13 billion people, with a prevalence of more than 150 million in Europe. 
In the adult population, the overall prevalence of hypertension was between 35-40%, 
with a standardized prevalence of 24% for men and 20% for women. As age increases, 
hypertension is more common, with a prevalence of >60% in people older than 60 years 
Due to the ageing of the population, more sedentary lifestyle habits adopted and the 
tendency to overweight, it was estimated that hypertension prevalence between 2000 
and 2025 will rise by 10% (1,15).  
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In long term, hypertension is a risk factor for cardiovascular disease (CVD), which 
includes stroke, myocardial infarction, coronary artery disease, heart failure, among 
others; and kidney disease (1,11,14). It is considered therefore one of the leading causes 
of death globally and on the European continent (2).  
5.2.2. Blood pressure classification  
In table 1 there is the classification of BP, used for all ages group from 16 years.  Hence, 
hypertension is defined when SBP values are ≥140 mmHg and/or DBP value are ≥90 
mmHg.  
 
Table 1. Blood pressure values: classification and definitions of hypertension grades (2).  
Category Systolic (mmHg)  Diastolic (mmHg) 
Optimal <120 and <80 
Normal 120-129 and/or 80-84 
High normal 130-139 and/or 85-89 
Grade 1 hypertension 140-159 and/or 90-99 
Grade 2 hypertension 160-179 and/or 100-109 
Grade 3 hypertension ≥180 and/or ≥110 
Isolated systolic hypertension ≥140 and <90 
 
On the other hand, isolated systolic hypertension occurs when only SBP rises, most 
commonly in the elderly. It is graded 1,2 and 3 according to SBP ranges indicated in Table 
1 (2).  
While SBP rises with age, DBP decline after 55 years of age. Resistant hypertension is a 
condition in which BP is uncontrolled despite the current use of typical treatments and 
therapies (14).  Borderline hypertension occurs when SBP and DBP values are over 130 
mmHg and 80 mmHg, respectively and it is associated with increased risk of progression 
to later established hypertension as well as increased risk of cardiovascular mortality 
(16).  
5.2.3. Aetiology  
Hypertension is a multifactorial disorder in which family history is an important aspect 
to consider. Most studies indicate that heritability ranges between from 30-35% (2).  
However, there are other factors that contribute to the development of hypertension 
and its consequent complications. Behavioural risks factors including unhealthy diet, low 
physical activity, alcohol consumption, tobacco use and high mental stress are 
associated with hypertension. Dietary habits such as excess of sodium intake and poor 
intake of calcium, potassium, protein (especially those coming from vegetables), fibre 
and fish fats, can cause or aggravate the condition. Gut microbiota seems also to be 
linked to the pathogenesis of hypertension (3,17). 
In addition, there are metabolic factors like overweight, obesity, diabetes or 
hypercholesterolemia that increase the risk of CVD. Metabolic syndrome (MetS) is a 
chronic disorder characterised by a clustering of pathological problems, mainly insulin 
resistance together with abdominal obesity, high triglycerides (TGs) and low high-
density protein (HDL) cholesterol levels and hypertension. The combination of these 
clinical findings has an increased risk of developing type-2 diabetes and CVD. In this case, 
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the BP values considered to determine hypertension are ≥130 mmHg SBP and ≥85 
mmHg DBP (3,18).  
Socioeconomic factors, e.g. income, education and housing are determinants for the 
development of hypertension as they negatively influence behavioural risk factors. 
Living and working conditions can retard the detection of the disease and its treatment, 
which impedes the prevention of high blood pressure complications. Moreover, fear of 
unemployment often causes stress levels that have a negative effect on BP (3).  
The risk of hypertension increases with ageing since blood vessels tend to stiffen over 
the years. This stiffening process is produced, among other factors, by vascular collagen 
changes and an increase in atherosclerosis. Even though, ageing of blood vessels can be 
delayed by healthy lifestyle habits, including healthy eating (1,3).  
 
Figure 4. Main risk factors that contribute to the development of hypertension and its 
complications, adapted from (3). 
According to its aetiology, hypertension is classified into two forms: primary or essential 
hypertension and secondary hypertension. In primary hypertension, the specific cause 
of high BP cannot be determined. By contrast, secondary hypertension is the 
consequence of other disease such as renal parenchymal disease, renovascular disease 
(including renal artery stenosis), primary aldosteronism, obstructive sleep apnoea and, 
less frequently, pheochromocytoma, Crushing’s syndrome, hyperthyroidism, aortic 
coarctation (11,14,17).  
Other terms used to describe high BP are malignant and transient or labile hypertension. 
Malignant hypertension is defined as unexpected increase in diastolic pressure above 
125 mmHg which can cause damage to the brain, heart, eyes and kidney. Transient or 
labile hypertension is a temporarily rise in BP by the emotional reaction and stressful 
situations to the clinical environment (14).  
5.2.4. Clinical manifestations and complications 
Hypertension is a disease that develops silently while destroying the wall of blood 
vessels, which is why it is known as the “silent killer”. In general, hypertensive patients 
do not experiment any symptoms, especially during the early stages of the disease. 
When symptoms appear, they are usually complications. However, there is an 
intermediate phase in which hypertension can cause clinical manifestation such as 
morning headache, exertional dyspnoea, feeling of dizziness when changing position, 
chest pain, heart palpitations and epistaxis. It is important to not ignore these symptoms 
but it is important to bear in that, on their own, they do not necessarily indicate 
hypertension (3).  
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5.2.4.1. Complications: target-organ damage  
The higher BP levels are, the more probability to damage blood vessels in major organs 
such as the heart, brain, retina and kidneys. This cardiovascular risk is also dangerous in 
people suffering mild hypertension but with other risk factors like smoking, physical 
inactivity, unhealthy diet, obesity, diabetes, high lipid profile, among others (3).  
In heart, clinical complications such as acute myocardial infarction, acute LV failure with 
pulmonary edema, unstable angina pectoris or dissecting aorta aneurism, can occur. 
Brain damage may result in hypertensive encephalopathy, intracerebral haemorrhage 
(ICH) as well as ischaemic stroke. In eyes, hypertensive retinopathy may develop which, 
due to an increased BP, can damage the retina causing bleeding to blindness. Persistent 
high BP can severely damage the kidney leading to renal failure (17).  
5.2.5. Pathogenesis  
The pathological mechanisms involved in hypertension are complex. In primary 
hypertension there is a genetic predisposition, as multiple genes are associated with 
higher risk of hypertension and are positively related to family history. This, together 
with environmental factors, contributes to suffer from hypertension (1). 
a. Salt sensibility  
The concentration of sodium in serum promotes fluid retention, which leads to an 
increase in blood volume and, consequently, an increase in BP. In normotensive 
individuals, when dietary sodium increases, compensatory haemodynamic changes 
occur to maintain BP at its physiological values. These changes consist of the reduction 
of vascular resistance, both renal and peripheral, as well as the increase in NO 
production by the endothelium. Nevertheless, endothelial dysfunction can lead to salt 
sensibility and, thus, hypertension. Salt-sensitive individuals, in order to cope with a high 
salt load, present an overproduction of the TGF β (transforming growth factor-β), 
responsible for increasing the risk of fibrosis, oxidative stress and low NO concentration  
(1,19). 
Endothelial dysfunction can result from chronic high salt intake and may modify the 
intestinal microbiota, bringing with it changes that contribute to salt sensibility and 
subsequent high blood pressure. It seems that salt sensibility can induce T-helper 17 
(TH17) cells, causing autoimmunity (1,19).  
b. Renin-angiotensin-aldosterone system (RAAS) 
RAAS plays a crucial part in the pathogenesis of hypertension, in which ANG II is the main 
element of this pathogenic role. Apart from enhancing sodium reabsorption at renal 
level, ANG II is also related to endothelial dysfunction as well as pro-inflammatory and 
pro-fibrotic effects due to oxidative stress. This can lead to vascular, kidney and heart 
injury, which is why ANG II is strictly associated target-organ damage in hypertension. 
Aldosterone is a key element in the genesis of hypertension. It stimulates sodium 
reabsorption, but also contributes to endothelial dysfunction and vasoconstriction by 
inducing vascular smooth muscle cell proliferation, vascular fibrosis and oxidative stress 
(1).  
c. Endothelium  
In hypertension, circulating ET1 levels do not necessarily increase but what has been 
noticed is that, in hypertensive individuals, the sensitivity to the vasoconstricting effects 
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of ET1 is higher. In experimental models of hypertension, ETA blockers have 
demonstrated to be effective in attenuating or eradicating the disease and lowering BP 
in humans (1,20,21).  
Endothelial dysfunction plays an important role in the development of hypertension. It 
is the result of damage induced by pressions in combination with oxidative stress. 
Various factors such as ANGII, vascular stretching due to cyclic changes in BP, ET1, uric 
acid, systemic inflammation, noradrenaline, free fatty acids and smoking habit, 
contribute to the generation of oxidative stress in hypertension by activating NADPH 
oxidase, an enzyme that generates ROS. Increased bioavailability of ROS decreases NO 
levels, leading to endothelial dysfunction and hypertension (1,22). 
d. Sympathetic Nervous System  
In general, SNS activation is higher in hypertensive individuals rather than in 
normotensive people. Patients with hypertension often suffer from an autonomic 
imbalance with increased SNS and decreased PNS activity. This SNS overactivity is 
responsible for both the generation of hypertension and its maintenance, since it implies 
increased renal sympathetic nerve activity and, consequently, increased renal 
reabsorption of sodium (Figure 3) (1,23,24).  
Moreover, SNS hyperactivity, by activating α1 adrenergic receptor, induces endothelial 
dysfunction, vasoconstriction, vascular smooth muscle proliferation arterial rigidity, also 
contributing to the development of hypertension (1).  
e. Inflammation and the immune system 
An inflammatory process increases vascular permeability and involves the release of 
inflammatory mediators such as cytokines, ROS and NO. Cytokines promote vascular 
fibrosis by increasing vascular resistance and stiffness. Furthermore, they stimulate 
renal synthesis of angiotensinogen and, thus, of ANG II. Still, the link between 
inflammation and hypertension is complex and the scientific evidence in humans is 
limited. It appears that C-reactive protein, TNF (tumour necrosis factor) and diverse 
interleukins are associated with hypertension but without a direct relationship (1).  
5.2.6. Diagnosis and prevention 
Primary hypertension is an asymptomatic condition that frequently, is diagnosed in 
lately states. It is usually detected in population screening programmes or because of 
opportunistic measurement of BP (2).  
BP should be screened regularly in office visits, particularly in adult population. Those 
patients with optimal BP levels (<120/90 mmHg), should remeasure their BP every 5 
years or more frequently if the opportunities arise. For patients with normal BP (120-
129/80-84 mmHg), it is recommended to record their BP every 3 years. Patients with 
high-normal BP (130-139/85-89 mmHg), should record their BP annually due to high 
probabilities of progression to hypertension (2).  
In almost all patients, repeated BP readings in office visits is the strategy to confirm the 
persistent increase of BP. The frequency and intervals between visits will vary depending 
on the diagnosed hypertension stage and whether there is a risk of CVD or hypertension-
mediated organ damage (HMOD). Thus, BP diagnosis should also include assessment of 
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CVD risk, HMOD and concomitant clinical conditions that could suggest secondary 
hypertension (2,11).  
Home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring 
(ABPM) are out-of-office BP measurement methods increasingly introduced during last 
decade to guide diagnosis and treatment of hypertension (Table 2). They provide 
estimates based on several BP readings under conditions representative of daily life. 
HBPM is based on BP measurements at regular intervals performed by the same patient 
at home or elsewhere outside the clinical setting. ABPM refers to the recording of BP at 
regular intervals (usually every 15 or 30 minutes) during a typical 24-hours period while 
individuals perform their daily activities. BP follows a circadian rhythm and dips during 
sleep. As ABPM provides night time readings, it is considered to have stronger 
prognostic evidence than office BP measurement (1,2).  
Table 2. Definitions of hypertension based on 2018 ESH/ESC guidelines (2). 
Category Subtype Systolic BP (mmHg) Diastolic BP (mmHg) 
Office BP NA ≥140 ≥90 
Ambulatory BP 
Daytime (awake) ≥135 ≥85 
Night-time (asleep) ≥120 ≥70 
24h ≥130 ≥80 
Home BP NA ≥135 ≥85 
 
 
 
Out-of-office BP measurement methods has made it possible to detect different BP 
phenotypes like white-coat hypertension and masked hypertension. White-coat 
hypertension is characterised by high BP in the doctor’s office, but normal when 
measured by HBPM or ABPM. On the contrary, masked hypertension refers to the 
untreated condition in which BP is normal for in-office readings but elevated for out-
office readings (1,2). 
Because of the relationship between CVD risk high BP, it is important to treat 
hypertension as soon as possible. It is also of high importance, to implement strategies 
to lower CVD risk in patients having high BP levels, but below the threshold for 
hypertension. In this way, it is possible to prevent CVD risk and decrease the tendency 
to develop hypertension with aging (11).  
5.2.7. Treatment  
Frequently, hypertensive patients have comorbid medical conditions, which means that 
multiple chronic or acute diseases are present. For this reason, these patients often 
require more than one medication for their proper treatment. Among the comorbid 
conditions diabetes mellitus is the most common (14).   
Pharmacological antihypertensive therapy can be highly effective in lowering BP and its 
associated risks. Nevertheless, changes in lifestyle can be equally effective in reducing 
and preventing hypertension and CVD outcomes (1).   
For the diagnosis of hypertension, Systolic BP, Diastolic BP or both have to exceed the reported 
values. BP, Blood Pressure; ESC, European Society of Cardiology; ESH, European Society of 
Hypertension; NA, not applicable. 
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5.2.7.1. Non-pharmacological strategies 
The most successful non-pharmacological interventions are weight-loss, dietary salt 
restriction, increased potassium intake, regular physical exercise, moderation of alcohol 
consumption, smoking cessation and diets that combine elements to prevent high BP.  
The most significant evidence is provided by the DASH-sodium trial in which the 
combination of low-sodium intake and Dietary Approaches to Stop Hypertension (DASH) 
diet (a diet based in fruits, vegetables and low-fat products, especially low-saturated fats 
and cholesterol), was associated with significant reductions in BP (1,2,17).  
Some other diets, including low-calorie diets, vegetarian diets and the Mediterranean 
pattern, in which olive oil plays a key role as a main source of fat, have also been shown 
to lower BP and improve hypertension control. The DASH diet and MedDiet share 
similarities, but with the difference that the latter is enriched with olive oil rather than 
other vegetable oils and sources of fat (17,25,26). The MedDiet as a measure to combat 
high blood pressure, will be further developed in the point 5.3.1 below.  
5.2.7.2. Pharmacological therapy  
In addition of lifestyle changes, a lot of patients requires drugs to control their BP. 
Typically, antihypertensive therapy starts with first-line medications, either 
monotherapy or in combination. Combination is the therapy of choice in those patients 
with higher BP levels prior to treatment (1,2).  
Among antihypertensive first-line medications, the most prescribed drugs are diuretics 
(thiazides-like), Angiotensin Converting Enzyme inhibitors (ACE inhibitors), Angiotensin 
II Receptor Blockers (ARBs, also called sartans), calcium antagonists (dihydropyridines, 
verapamil, diltiazem), β-blockers and α-β adrenergic blockers (1,2,14).  
Recommendations to initiate BP-lowering treatment, including lifestyle changes and 
drug-treatment, are shown in Figure 1 (2).  
Figure 5. Initiation of bp-lowering treatment (lifestyle changes and medication) at different 
bp levels, adapted from (2). 
BP, Blood Pressure; CVD, Cardiovascular Disease; HMOD, Hypertension-Mediated Organ Damage  
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5.3. FINDING POTENTIAL THERAPEUTIC TOOLS IN THE PREVENTION AND 
TREATMENT OF HYPERTENSION  
In spite of genetic predisposition to primary hypertension, environmental factors such 
as poor dietary habits, high sodium intake, poor sleep quality or sleep apnoea, excessive 
alcohol consumption, lack of physical activity and mental stress, contribute to the 
development of hypertension. For this reason, a healthful lifestyle is the essential 
strategy for the prevention and reduction of hypertension and dietary habit is the 
modifiable element with  the greatest effect on BP (1,6,27).  
Given that most hypertensive patients need to take more than two anti-hypertensive 
drugs to reduce their BP to an acceptable level (<140/90 mmHg), which also implies an 
increased risk of adverse drug effects and medication costs, it is important to consider 
other therapeutic tools. The use of potential natural products such as herbal medicine 
and food supplementation could be a good alternative to treat hypertension (28,29).  
5.3.1. The Mediterranean diet  
The MedDiet is a typical diet of the Mediterranean region. Its main components are 
vegetables, fresh fruit, whole grains, fish and seafood, legumes, nuts, extra virgin olive 
oil and moderate dairy products as well as red wine consumption. In this dietary pattern, 
products considered to have unfavourable effect on the risk of hypertension like red 
meat, processed meat and poultry are limited foods (6).  
Adherence to the MedDiet is widely associated with long-term benefits such as reduced 
total mortality, cancer, neurodegenerative diseases, hypertension and its subsequent 
risk of CVD. It has protective mechanisms of the cardiovascular system that include 
hemodynamic, metabolic and inflammatory effects (25). 
Some studies have shown that people who adopt MedDiet have lower BP, oxidized low-
density lipoprotein (LDL), inflammatory markers and arterial stiffness as well as better 
endothelial function (6,25,30).  
Although the influence of the MedDiet is due to the combination of complete dietary 
patterns, olive oil is one of the component that has the most favourable effect on BP (6). 
Moreover, olive leaves have been used as a folk medicine for the treatment of 
hypertension (8). 
 
5.4. Olea europaea L., A POTENTIAL THERAPEUTIC TOOL IN THE 
PREVENTION AND TREATMENT OF HYPERTENSION 
5.4.1. Introduction  
The olive tree (Olea europaea L.) is a plant widely-distributed, especially found in the 
Mediterranean region, used for the production of olive oil, table olives and other by-
products (8). It belongs to the Oleaceae family, order Lamiales, which includes 30 genre 
and about 600 species of trees and shrubs. Among them, Olea europaea L. is the only 
specie producing edible fruits and is, therefore, used as food (7,31).  
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Olea europaea L. is originated in the coast of the eastern Mediterranean basis, but also 
in northern Iran, Asia Minor and northern Africa. However, nowadays, it is cultivated 
around the world, above all, in the Mediterranean area such as Greece, Spain, Italy, 
France, Turkey, Israel, Morocco and Tunisia, Asia-Pacific and South and North America 
(8,31,32).  
Olive tree has been cultivated since ancient times as it dates back for more than 7,000 
years ago. Its olives fruits, oil and leaves have been an important part of the human diet 
and traditional medicine, due to its nutritional and therapeutic properties (8,31). During 
the last decades, the demand of its products has increased because it is linked to the 
prevention of various pathologies associated with oxidative stress, like cancer, CVD, 
metabolic disorders as well as inflammation (7).  
5.4.2. Olea europaea L. botanical description 
Olive tree is a monoecious specie of evergreen. It is a short and thick tree or shrub about 
10 m high. The leaves are simple, lathery, lanceolate with entire margin, dark green 
colour in the front and silver/whitish in the back. Their length and width are variable 
between 3-8 cm and 1-2 cm respectively (31).  
The blooming starts at the beginning of March, but real flowers come out in April-May. 
The flowers are numerous, either bisexual or functionally unisexual. They are small, 
actinomorphic and creamy white flowers of radiated symmetry. Olives fruits are drupes 
of oval shape and size about 1-4 cm long and 0,6-2 cm in diameter. They are composed 
of three main structures: a lignified endocarp, which contains the seed; a mesocarp or 
pulp, which contains the oil; and an epicarp or skin (7,31).  
5.4.3. Olive fruit 
Olives are the fruits produced by the olive tree (Olea europaea L.). They cannot be eaten 
in their natural raw form due to their extreme bitterness and require specific processing. 
Despite most of the harvested crops are destined to the production of olive oil, smaller 
amounts are processed to be consumed as table olives (7).  
In order to make them edible, table olives are fermented, pickled in brine or cured in 
salt. They are traditionally produced in Mediterranean countries and, unlike other 
fermented foods, their content is low in sugar (2-5%) and high in fat (20-35%), mostly 
monounsaturated fatty acids (MUFAs). Nevertheless, olives are considered a moderate 
source of calories since 100 g of fruits provide only 115 calories. Depending on the 
production method there are different types of olives with different tastes, typically 
bitter due to the presence of oleuropein and oleocanthal (7,8).  
The composition of table olives has a high nutritional value as it includes lipids, sugars, 
proteins as well as water and some minerals (7). In addition, they contain non-nutritional 
components on which beneficial effects for human health have been described. This 
non-nutritional fraction represents approximately 3% of their weight and is composed 
mainly of phenolic compounds, the majority of which are phenolic acids and alcohols, 
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secoiridoids and flavonoids. Among the most important individual compounds there are 
hydroxytyrosol derivates, oleuropein, verbascoside and ligstroside (7,8,31).  
5.4.4. Olive oil  
Olive oil is the chief product of the olive industry. According to its free acidity, the 
standard grades available on the market are extra virgin olive oil (EVOO), virgin olive oil 
(VOO), refined olive oil and pomace oil. This latter is the remaining product after the 
mechanical extraction of EVOO and VOO. EVOO is the purest and most expensive olive 
oil type, with an acidity of ≤0,8 g/100g expressed as oleic acid (7,8,31,33).  
Olive oil is a complex mixture of more than 230 different chemical compounds. Glycerols 
are the main fraction, comprising a high proportion of MUFAs and polyunsaturated fatty 
acids (PUFAs) as well as minor compounds such as phenolic compounds and tocopherol 
(vitamin E). In addition of having rich-lipid content, olives are an important source of 
vitamins and minerals including calcium, iron, potassium, sodium and vitamins E and K 
(7,8,31).  
In general, olive oil has a high nutritional value. Since olive varieties, growing conditions 
and environmental factors can be very variable, not all olive oils have the same chemical 
composition (7,8,31).  
EVOO and VOO consumption has been related to the reduction of BP as well as 
cholesterol levels and other risks factors which contribute to CVD. These biological 
benefits are mainly attributed to their MUFAs content but also to their minor 
constituents such as hydrocarbons, phytosterols, triterpenic compounds and phenolic 
compounds (4,33,34).  
5.4.5. Olive leaves  
Olive leaves are rich in bioactive compounds in which polyphenols and flavonoids have 
shown health benefits such as anti-carcinogenic, anti-hypertensive, anti-inflammatory 
and antimicrobial effects. Traditionally, infusions of olive leaves have been used as 
antihypertensive remedy to palliate the effects of atherosclerosis, arthritis, arthralgias, 
gout and diabetes (8,35).  
5.4.6. Effect of bioactive compounds of Olea europaea L. on blood pressure 
Many natural compounds from Olea europaea L., in particular from its leaves, have been 
found to have a hypotensive effect. The effects found by main bioactive compounds of 
Olea europaea L. such as oleic acid, pentacyclic triterpenes and polyphenols are 
explained below.  
Moreover, at the end of this revision, Table 4 summarizes the effects found in preclinical 
studies using different experimental models and Table 5 compiles the obtained results 
in relevant human clinical studies.  
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5.4.6.1. Oleic acid and fatty acids  
Distribution in Olea europaea L. 
The main fatty acids isolated from the fruits of Olea europaea L. are oleic acid, palmitic 
acid, linoleic acid and stearic acid, respectively. VOO contains a large part of MUFAs, 
with a high proportion of oleic acid (70-80%), which is integrated into TGs (8,31,33,36). 
   
Effects on blood pressure 
Long-term consumption of VOO has been shown to decrease BP and prevent 
hypertension. It has been observed that oleic acid can activate α and β-adrenergic 
receptors and its signalling pathways. Nevertheless, some studies have claimed that 
olive oil cardioprotective effect is due to minority compounds such as α-tocopherol and 
polyphenols (36,37).  
Teres et al. (2008) demonstrated that the increase of oleic acid in cell membranes, 
thanks to the intake of olive oil, regulates the structure of the lipid membrane and, in 
this way, G-protein associated signalling is regulated causing a hypotensive effect (Table 
4). The experiment was designed in order to investigate VOO effect at the molecular 
level and it was found that a higher concentration of MUFAs activates the expression of 
adrenergic receptors signalling pathways stimulating vasodilatory pathways but 
restricting vasoconstrictive pathways. VOO, oleic acid and triolein, a dominant TG with 
three molecules of oleic acid, were administered for 14 days to rats and all showed a 
similar BP lowering activity. However, elaidic acid, stearic acid and soybean oil (which 
contains a small portion of oleic acid) had no hypotensive activity, suggesting that the 
molecular mechanisms associated with lipid membrane and BP regulation have high 
structural specificity (36). 
In 2013, Miura et al. conducted a cross-sectional epidemiologic trial with the aim of 
linking MUFAs intake and BP reduction. This International Study of 
Macro/Micronutrients and Blood Pressure (INTERMAP) involved 4680 men and women 
aged 40-59 years from 17 different samples from Japan (four samples), China (three 
samples), UK (two samples) and USA (eight samples). Volunteers attended four visits 
and, in each of visit, BP was read in an average of two measurements. On the basis of 
the results obtained, researchers reached the conclusion that daily MUFAs intake, 
especially those coming from plant sources and for patients without undergoing medical 
or nutritional intervention, contributes to the prevention and control of high blood 
pressure (Table 5). For this reason, these findings support dietary recommendations 
based on increased consumption of vegetable MUFAs (38). 
5.4.6.2. Pentacyclic triterpenes  
Distribution in Olea europaea L. 
Pentacyclic triterpenes are compounds widely distributed in more than 120 plant 
species, some of them used in the traditional medicine. In Olea europaea L., triterpenic 
compounds are present in olives, leaves and VOO. Among the minor compounds of VOO, 
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triterpenic compounds represent one of the chief bioactive components. However, they 
are found in higher concentration in olive leaves (39,40) .  
Effects on blood pressure 
Somova et al. (2003) reported the beneficial properties of four triterpenoids derivatives 
extracted from African and Cape cultivar Olea europaea L. leaves: uvaol (UV), ursolic 
acid (UA), oleanolic acid (OA) and methyl maslinate (MM). All of them showed a 
significant, dose-response, vasodepressor effect in a resistant-insulin rat model. They 
acted by blocking the effect of adrenaline and isoprenaline and, thus, suggesting its 
activity as β-adrenergic antagonists (Table 4). The strongest effect was from OA and MM 
(39).  
Pomace oil, as a result of the refining process, has a different composition to EVOO and 
VOO for certain components. It lacks polyphenols but has a higher concentration of 
pentacyclic triterpenes. Valero-Muñoz et al. (2014), aimed to evaluate the protective 
effects of a pomace oil rich in triterpenic acids (OA and maslinic acid) on BP, cardiac 
haemodynamic parameters and vascular alterations caused by hypertension in SHR 
(spontaneously hypertensive rats), an established genetic model of hypertension. 
During 8 weeks, the animals received a dose of pomace oil containing 100 mg/kg/day of 
triterpenic compounds in which 56.8 mg/kg/day was OA and 38 mg/kg/day was maslinic 
acid. At the end of the experiment, SHR did not experience an increase in BP while HR 
was similar in both the treatment and control groups. Additionally, results showed an 
improved endothelial function, with an increased eNOS (endothelial Nitric Oxid 
Synthase) expression as well as improved cardiac haemodynamics regarding to SBP and 
DBP (Table 4). In conclusion, this study confirmed the potential cardiovascular benefits 
of an enriched triterpenoid pomace oil, a waste product of the olive oil industry, raising 
awareness of its biological and nutritional values (41). 
Literature has described useful pharmacological properties of OA and has reported its 
BP lowering in normotensive animals. Thus, due to its therapeutic potential, OA has 
been suggested as a starting point for the synthesis of new derivatives. Madlala et al. 
(2015) made a comparison between the effects of OA administration on MAP and kidney 
function with those obtained with oleanane synthetic derivatives (brominated OA, Br-
OA and OA-methyl ester, Me-OA) administration in normotensive animals. In terms of 
reducing MAP and improving renal function by increasing sodium excretion, acute 
infusion of OA and its oleanane derivatives had similar effects. Besides, sub-chronic oral 
OA treatment induced hypotensive responses in Wistar, DSS (Dahl salt-sensitive) and 
SHR rats. The OA lowering effect of MAP and oxidative stress was more noticeable in 
hypertensive animals and correlated with an increase in urinary sodium diuresis (Table 
4). Thereby, this work revealed the correlation between BP and increased urinary 
sodium excretion by OA and a more marked hypotensive effect of OA in hypertensive 
animals. It was considered a study of clinical relevancy as OA was effective by oral 
administration  (42). 
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5.4.6.3. Phenolic compounds 
Distribution in Olea europaea L. 
Olive fruits accumulate oil in the mesocarp in a percentage of 28-30%, but also contain 
secondary metabolites like phenolic compounds. The most abundant phenolic 
compounds are oleuropein, tyrosol and hydroxytyrosol. While the fruits and leaves of 
olives are rich in oleuropein and hydroxytyrosol, in olive oil the amounts of these 
compounds are lower, as they are soluble in water and end up in mills waste water of 
the production process (7,43).  
The high level of phenolic compounds plays a key role in defence and survival of olive 
plant, especially in its early stages when fruits are more vulnerable to attacks by insects 
and pathogens. Moreover, both hydroxytyrosol and oleuropein have a high antioxidant 
and scavenging activity against ROS (reactive oxygen species), hence, many human 
health benefits have been attributed to olive oil for its phenolic content. Hydroxytyrosol 
contributes to the prevention of atherosclerosis and heart-coronary disease as it inhibits 
the expression of LDL oxidation (43).  
 
Figure 6. Classification of the main phenolic compounds of Olea europaea L. (7).  
Contrary to olive oil, olive leaf contains the polyphenol fraction with only small 
quantities of oleic acid. Thereby, olive leaves represent a good opportunity to study the 
effect of olive oil polyphenols on the cardiovascular function, in particular on BP (44).  
Effects on blood pressure 
Moreno-Luna et al. (2012) conducted a dietary-intervention study using a polyphenol-
rich olive oil in order to analyse its influence on BP and endothelial function. The study 
participants were 24-year-old women in high-normal BP category or in stage 1 essential 
hypertension. The study was double-blinded, crossover and randomized and consisted 
of two different diets, one with a dose of ≈30 mg/day of olive oil rich in polyphenols and 
the other with olive oil free of polyphenols. Each dietary-period had a duration of 2 
months with 4 weeks of washout in between. The parameters measured during the 
study were: SBP, DBP, serum or plasma biomarkers of endothelial function, oxidative 
stress and inflammation and ischemia-reactive hyperaemia (IRH) in the forearm. The 
baseline values were taken during a 4-month run-in period. Compared to baseline 
Polyphenols in 
Olea Europaea L. 
Polar phenols
Phenolic acids Phenolic alcohols
Tyrosol
Hydroxytyrosol
Secoiridoids
Oleuropein
Ligstroside 
Flavonoids Lignans
Non-polar 
phenols
α-tocopherol
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values, results found a significant decrease (p<0.001) in SBP and DBP after 2 months of 
daily consumption of polyphenol-rich oil. Significant decrease in asymmetric 
dimethylarginine, LDL-oxidation and plasma C-reactive protein was also found, as well 
as a significant increase in plasma nitrites/nitrates and IRH, showing an improvement in 
endothelial function and oxidative status (Table 5). This study, showed for the first time 
that, a daily intake of small amount of polyphenols contained in olive oil during the early 
stages of hypertension, can have similar BP-lowering effects as first-line 
antihypertensive drugs usually prescribed (45). 
Valls et al. (2015) compared the effect on endothelial function of a functional virgin olive 
oil (FVOO) enriched with its own polyphenols with the effects of a standard VOO with 
polyphenol moderate content, in a randomised, double-blind and crossover trial. 
Thirteen volunteers with mild hypertension received a postprandial dose of 30 ml FVOO 
with a polyphenol content of 961 mg/kg and VOO with a polyphenol content of 289 
mg/kg. Five hours after ingesting the olive oils, endothelial function was measured as 
ischemic reactive hyperaemia (IRH), along with associated biomarkers. Comparing both 
interventions, IRH values increased (p<0.05) after FVOO consumption while oxidised LDL 
was decreased (p=0.01). So, FVOO shown healthier effects in contrast with standard 
natural VOO (Table 5) (46).  
a. Oleuropein  
Secoiridoids represent an important part of the leaves and fruits of Olea europaea L. 
They are a phenol-conjugated compounds that may contain a glycoside part. 
Secoiridoids come from the opening of iridoids cyclopentane ring and, in Oleaceae 
family, the resulting carbonyl group oxidizes and conjugates with a phenolic moiety (43).  
The most abundant secoiridoid is oleuropein aglycon, present in large quantities in olive 
leaves but in lower quantities in olive oil. Nevertheless, oleuropein is one of the major 
phenolic compounds present in olive oil and together with hydroxytyrosol and tyrosol 
represent 90% of the phenolic fraction. (7,31,43). 
Under in vitro conditions, oleuropein has demonstrated a range of beneficial properties 
for the cardiovascular system, among them, enhanced NO concentrations and 
decreased BP. This compound can be obtained from the decoction of olive leaves and in 
clinical trials has proved to be one of the components responsible for causing 
vasodilation on isolated rat aorta. In addition, it has shown an ACE inhibitory activity 
that may contribute to its BP-lowering effect (44,47).  
b. Flavonoids 
Flavonoids are polyphenolic substances which are responsible for a wide variety of food 
health benefits, including protection against atherosclerosis and CVD. Hypotensive 
properties of flavonoids from Olea europaea L. fruits and leaves have been found. Even 
though these pharmacological effects been mainly attributed to oleuropein, the 
presence of flavonoids derivatives is also crucial (48,49).  
Loizzo et al. (2007) attempted to analyse ACE inhibitory activity by flavonoids. The 
research Ailathus excelsa (Roxb) leaves plant were used for the extraction of six 
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flavonoids, some of which are also present in Olea europaea L. Then, the in vitro 
inhibitory activity toward ACE by MeOH extract and the isolated compounds was 
evaluated. All of them displayed ACE inhibitory activity in a dose-dependent way, 
showing potential antihypertensive activity (Table 4) (49). 
Furthermore, flavonoids perform inhibitory activity of lipid peroxidation, platelet 
aggregation and enzyme systems such as cyclooxygenase (COX) and lipoxygenase, and 
also reduce the capillary permeability and fragility. For this reason, flavonoid 
preparations have been used for years in clinical practice to treat circulatory disorders. 
Flavonoids are also potent antioxidants, free radical scavengers and divalent cations 
chelators. It has been suggested that the inactivation ACE activity by flavonoids is 
through the generation of chelated complexes with zinc ions within the ACE active 
centre (48,49).   
It seems that the biological mechanisms in which flavonoids modulate the vascular 
activity and BP are involved with NO production by the regulation of RAAS in VSMCs. 
However, as the actual mechanisms of ACE inhibition and the relevance of flavonoids 
for their supposed antihypertensive activity have not been fully established, further 
investigation is needed (49).   
5.4.6.4. Olive Leaf Extract  
Recent studies suggest the use of olive leaf extract (OLE) concentrated in phenols as a 
dietary supplement to reduce blood pressure, hyperglycaemia, oxidative stress, 
inflammation and, in turn, improve the lipid profiles and vascular function. This extract 
contains the same phenolic compounds as olive oil, but in higher concentrations. The 
predominant compound is oleuropein, but flavonoids including luteolin, apigenin and 
quercetin, as well as triterpenoids (oleanolic, ursolic and maslinic acid), are also 
important compounds in the antihypertensive activity of OLE. Olive leaves offer the 
possibility of providing good absorption and bioavailability of their phenolic content, 
which is a requirement for their bioactivity. Hence, the hypotensive effect of OLE has 
been studied up to now in different animal models (50,51).  
In a study carried out in 2002, a prepared OLE (EFLA® 943) was tested in order to 
investigate its BP lowering activity. The extract was tested in hypertensive rats by daily 
oral doses of L-NAME (NG-nitro-L-arginine methyl ester). The extract oral administration 
resulted in an antihypertensive effect related to reversal of vascular changes involved in 
L-NAME-induced hypertension (Table 4) (52).  
In 2008, the effects of commercial OLE were studied on isolated rabbit hearts. The 
results showed a concentration-dependent decrease of systolic left ventricular pression 
and HR as well as increase in relative coronary flow, due to the direct and reversible 
suppression of the L-type Ca2+ channel by OLE (Table 4) (53).  
A study conducted in 2014, aimed to investigate the immediate effects of the oral 
administration of a high dose of standardized OLE on blood pressure, HR and oxidative 
stress. In vivo models of SHR and normotensive Wistar rats (WR) were used. In the 
experiment, SBP and HR were measured before and after 60 and 120 minutes of 
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administration of OLE. Besides, in order to investigate the effects of OLE on the plasma 
lipid peroxidation and antioxidant system of erythrocytes in both rat strains, the 
erythrocyte activity of catalase, glutathione peroxidase, superoxide dismutase (SOD), 
glutathione reductase along with lipid peroxidation in plasma (pTBARS) were measured 
as well. The study results showed a significant difference (p<0,001) in the SBP and HR 
between WR and SHR. A high oral dose of OLE did not cause changes in BP or HR in 
normotensive rats. Conversely, the same dose in SHR, reduced BP by 20% and 13% after 
60 and 120 minutes of OLE administration, respectively (Table 4) (50).  
In hypertensive patients, it has been observed that haemodynamics alterations in 
carotid and renal arteries are related to the severity and extent of target organ damage. 
Studies have indicated that there is correlation between carotid vascular resistance and 
renal vascular resistance, which means that an increase of vascular resistance can 
develop in parallel in both vascular beds. Furthermore, oxidative stress is an important 
factor in the pathogenesis of CVD and, in human carotid arteries of older patients, ROS 
levels are higher. Some studies using models of hypertensive rats, have demonstrated 
that increased production of ROS in vascular tissue 
contributes to the development of hypertension 
and its maintenance (54). In 2016, Mihailovic et al. 
found that plant products rich in polyphenols lower 
BP and have beneficial effects on carotid artery 
alterations induced by hypertension (55).  
An experiment undertaken in 2016 by Romero et al. 
(56) that tested the chronic antihypertensive effects 
of an oleuropein-enriched (15% w/w) OLE in SHR. As 
secondary objectives, effects based on the 
improvement of endothelial function and 
antioxidant and anti-inflammatory properties on 
the vascular wall were also studied. In the 
experiment, ten Wistar Kyoto Rats (WKR) were used 
as control WKR group, ten WR as control WR group 
and ten WR were treated with OLE at a dose of 30 
mg/kg for 5 weeks. SBP, HR and cardiac hypertrophy 
were reduced after long-term treatment. Thanks to 
the reduction of pro-inflammatory and pro-
oxidative status and endothelial dysfunction 
through various mechanisms, OLE exerted 
hypertensive activity in SHR (Table 4) (56).  
Recently, Ivanov et al. (2018) examined the 
reducing activity, antioxidant capacity and metal ion 
chelating ability of a standardized oleuropein-
enriched OLE (16-24% oleuropein content) in SHR. 
As secondary aim, the study examined the extract 
Figure 7. Systolic arterial pressure 
(SAP), diastolic arterial pressure 
(DAP) and pulse pressure (PP) in SHR 
rats before and after treatments. 
Ivanov et al. (2018) (54). 
*p<0.005, **p<0.001, ***p<0.0001, significant 
difference between before and after treatment 
values 
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influence on haemodynamics, either regional or systemic, and its antihypertensive 
mechanism. Additionally, lipid profile and lipid peroxidation were also investigated. The 
observed effects were then compared with effects obtained using oleuropein alone 
(OP). OLE was applied at doses of 5, 25 and 50 mg/kg whereas OP was applied at the 
dose of 10 mg/kg. Acute in vivo effects on oxidative stress and carotid, renal and 
systemic haemodynamic parameters of BP, HR, CO and PVR were studied. Results 
showed that OLE possesses higher antioxidant activity than BHT (butylated 
hydroxytoluene), higher reducing capacity than vitamin C, which is a strong natural 
antioxidant, and lower metal-ion chelating activity than EDTA (54).  
Depending on the administered dose, two different antihypertensive responses were 
found. When SHR received the OLE dose of 25 mg/kg (OLE25), vascular resistance in 
systemic circulation was affected, resulting in a significant decrease in total PVR, thus 
also in SBP, DBP and MAP. By contrast, HR and CO parameters, which reflect cardiac 
mechanisms, occurred when 50 mg/kg OLE (OLE50) was applied. While in OLE25 the 
decreased BP was due to peripheral vasodilation, in OLE50 it was because of the 
reduction in HR, which leads to a decrease in CO and BP (54).  
Therefore, OLE25 was the most effective reducing cardiovascular risks, improving 
carotid and renal haemodynamics as well as PVR. OLE50, although caused improvement 
of cardiac function and BP, retained high vascular resistance, which reduced blood flow 
to the brain and kidneys of SHR. One the other hand, OP administration did not affect 
systemic or regional haemodynamics, 
indicating that other OLE constituents 
may be the responsible for cardiovascular 
and haemodynamics changes. These 
results are expressed graphically in Figure 
7 and summarized in Table 4 (54).  
Perrinjaquet-Moccetti et al. (2008) tested 
EFLA ®493 as a dietary supplement in 40 
borderline hypertensive monozygotic 
twins aged between 18-60 years. The 
investigation consisted of an open study 
of twin parallel groups. Two parallel 
experiments were conducted 
(experiment I and II) and, in both of them, 
twin pairs were randomly assigned to 
different treatment groups.  In 
experiment I, treatment group was 
administered daily on tablet of 500 mg of 
EFLA ®493 while did not receive 
medication but lifestyle suggestions to 
combat hypertension. In experiment II, 
one twin from each pair received a dose 
Figure 8. Mean differences of systolic blood 
pressure (a) and diastolic blood pressure (b) 
between group control and 500 mg EFLA ®943 
group (experiment I) and between 500 and 
1000 mg EFLA ®943 group (experiment II) in 
borderline hypertensive monozygotic twins. 
Perrinjaquet-Moccetti et al. (2008) (29) 
Mean values were significantly different from the initial 
values: *p<0.005 
 
Results and discussion 
 
 - 27 -  
of 500 mg/day of EFLA ®493 and the other was administered dose of 1000 mg/day of 
EFLA ®493. Both experiments lasted 8 weeks (29).  
Participants BP and HR were measured in initial screening, after the first week of 
treatment and, from the second week, every 15 days until the end of treatment. 
Depending on EFLA ®493 doses, BP values changed between the corresponding twin. In 
all subjects BP was reduced, but most significantly in those who received a higher dose 
of the extract. In addition, intake of 1000 mg/day of EFLA ®493 clearly showed a superior 
effect to recommendations on lifestyle changes (Figure 8). A reduction of total 
cholesterol was also found in all treatment groups on a dose-dependent basis. 
Therefore, this clinical trial confirmed the antihypertensive and cholesterol-lowering 
actions of OLE in humans (29).  
In 2011, a double blind, randomized clinical trial aimed to compare the tolerability and 
effectiveness of OLE (EFLA ®493) with the reference drug Captopril. The volunteers were 
patients with stage 1 hypertension. OLE was administered orally twice a day, at a dose 
of 500 mg, over a period of 8 weeks. Initially, Captopril was given at a dose of 12,5 mg 
twice daily, but after 2 weeks, according to the patients’ response to the treatment, 
Captopril dosage regimen would be increased to 25 mg twice daily. The results showed 
an important reduction in SBP as well as DBP from baseline to 8 weeks. Greater results 
were achieved on those subjects treated with OLE instead of Captopril. A significant 
reduction in the concentration of total-cholesterol and TGs was also noticed at the study 
dosage regimen of OLE 500 mg twice a day for 8 weeks (Table 5), showing agreement 
with the results of Perrinjaquet-Moccetti et al. (2008). This positive effect on cholesterol 
was not observed in Captopril treatment group (28). Table 3 provides a comparison 
between BP, total-cholesterol and TGs values at baseline and at the end of the study 
(28).  
Table 3. Baseline and final study values of systolic blood pressure, diastolic blood pressure, 
total-cholesterol and triglycerides levels. Adapted from Susalit et al. (2011) (28).   
Variables BaselineMean (SD) EndMean (SD) p 
Olive group (n=72) 
SBP (mm Hg) 145.0 (5.0) 133.5 (10.4) <0.001** 
DBP (mm Hg) 91.3 (5.1) 86.6 (6.9) <0.001** 
TC (mg/dl) 202.2 (34.6) 196.4 (32.0) 0.033* 
TG (mg/dl) 140.3 (68.2) 128.4 (63.8) 0.032* 
Captopril group (n=76) 
SBP (mm Hg) 144.7 (4.5) 130.9 (9.3) <0.001** 
DBP (mm Hg) 89.9 (6.6) 83.4 (7.1) <0.001** 
TC (mg/dl) 183 (27.5) 184.1 (30.2) 0.808 
TG (mg/dl) 119.5 (63.0) 118.2 (67.7) 0.800 
 
 
 
TC, total cholesterol; TG, triglycerides; V, visit; End of study, after 8-week treatment. 
*p<0.005 = significantly different; **p<0.001 = significantly different 
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Table 4. Summary of the antihypertensive effects of bioactive compounds of Olea europaea 
L. in preclinical studies. 
Preclinical studies 
Compound/matrix Model Dose Activity Reference 
Fatty acids 
Genetically modified animals 
VOO, oleic acid and 
triolein 
Female 
Sprague-
Dawley rats 
and SHR 
(n=10 in each 
group) 
2g/kg VOO, 1g/kg 
triolein, 1g/kg OA 
Reduction of SBP in short-term 
treatment by controlling G-
protein through the cell lipid 
membrane 
Teres et al. 
(2008) (36) 
Pentacyclic triterpenes 
Healthy animals 
Oleanolic acid (OA), 
ursolic acid (UA), uvaol 
(UV) and methyl 
maslinate (MM) 
Wistar Rats 
(n=6 in each 
group) 
Antidysrhythmic 
activity at a dose 
of 40 mg/kg (UV, 
OA) 
Cardiotonic and antidysrhythmic 
activity by β-adrenergic 
antagonism 
Somova et 
al. (2003) 
(39) 
Genetically modified animals 
Pomace olive oil rich 
in OA and maslinic 
acid 
22-week old 
male SHR 
(n=16) 
100 mg/kg/day 
of pomace oil 
from which:  
56.8 mg/kg/day 
OA and 38 
mg/kg/day 
maslinic acid  
Attenuation of the increase in BP 
by improvement of endothelial 
function (enhanced eNOS 
expression) and organ target 
protection 
Valero-
Muñoz et 
al. (2014) 
(41) 
OA and Me-OA, Br-OA 
Wistar, DSS 
(Dahl salt-
sensitive) and 
SHR rats 
(n=6 in each 
group) 
Acute (4h):  
Infusion 90 µg/h 
 
Subchronic (9h):  
OA doses of 30, 
60 and 120 
mg/kg, twice at  
9h and 15h, 
every third day 
for 9 weeks 
MAP-decreasing activity and 
increasing Na+ outputs 
Madlala et 
al. (2015) 
(42) 
Phenolic compounds 
Genetically modified animals 
Flavonoids In vitro assay 
53.78% inhibition 
at the 
concentration of 
330 µg/ml 
Hypotensive activity by ACE 
inhibition in a dose dependent 
way 
Loizzo et al. 
(2007) (49) 
Oleuropein enriched 
OLE 
WKR (n=10) 
and SHR 
(n=20) 
30 mg/kg OLE for 
5 weeks 
Reduction of BP, HR cardiac and 
renal hypertrophy related to the 
improvement of vascular function 
and pro- oxidative status and pro-
inflammatory cytokines  
Romero et 
al. (2016) 
(56) 
OLE and oleuropein 
alone (OP) 
24-week male 
SHR (n=7 in 
each group) 
5,25, 50 mg/kg 
OLE  
 
10 mg/kg OP 
Improvement of oxidative stress, 
cardiac function and BP in SHR 
Ivanov et al. 
(2018)  
(54) 
Olive Leaf Extract (OLE) 
Genetically modified animals 
Commercial OLE 
Isolated 
rabbit hearts 
n=5 samples 
n=4 control 
experiments 
1, 10, 20 and 50 
µM OLE 
Concentration-dependent 
decrease in LVP and HR by 
suppression of L-type Ca2+ 
channel in a direct and reversible 
way 
 
Scheffler et 
al. (2008)  
(53) 
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Table 4. Cont.  
Compound/matrix Model Dose Activity Reference 
Olive Leaf Extract (OLE) 
Genetically modified animals 
OLE 
Male, adult, age 
matched SHR 
and WR  
(n=8 in each 
group) 
200 mg/kg OLE 
Acute hypotensive and pro-
oxidative effect in SHR (increased 
pTBARS and SOD activity) 
Dekanski et 
al. (2014)  
(50) 
Hypertensive induced animals 
OLE L-NAME rats   
Different dose 
levels for 8 
weeks, 
best effects 
induced by 100 
mg/kg 
Dose dependent prophylactic 
effect against BP increase in L-
NAME model by reversal of 
vascular changes 
Khayyal et 
al. (2002)  
(52) 
 
 
 
Table 5. Summary of the antihypertensive effects of bioactive compounds of Olea europaea 
L. in clinical trials 
Clinical trials – Nutritional interventions 
Compound/Matrix 
Study design and 
subjects 
Dose Activity Reference 
Phenolic compounds 
Polyphenol-rich olive 
oil 
Double-blind, 
randomized, crossover  
 
24 young women aged 
24-27 years, with mild 
hypertension 
30 mg/day  
(2 months) 
Significant decrease in 
SBP and improvement 
of endothelial function 
by increasing NO 
bioavailability  
 
Antioxidant and anti-
inflammatory 
Moreno-Luna 
et al. (2012) 
(45) 
FVOO polyphenol-
enriched 
 Double-blind, 
randomized, crossover  
 
13 participants aged 
20-75 years with pre-
hypertension or stage 
1 hypertension 
30 ml FVOO 
with 961 mg/kg 
of phenolic 
compounds  
 
Acute effects (5h):  
Improvement of 
endothelial function 
 
Decrease in oxidised 
LDL concentrations and 
inflammatory 
biomarkers   
Valls et al. 
(2015) 
(46) 
Fatty acids  
MUFAs 
Cross-sectional 
epidemiological  
 
4680 participants aged 
40-59 years 
Daily MUFAs 
intake 
Prevention of high 
blood pressure  
 
Better BP control in no-
intervened individuals 
and with MUFAs from 
vegetable sources 
Miura et al. 
(2013) 
(38) 
Olive Leaf Extract (OLE) 
EFLA 943® 
40 borderline 
hypertensive 
monozygotic twins 
500 or 1000 
mg/day for 8 
weeks 
Hypotensive effect with 
better activity in high 
dose treatment group 
Perrinjaquet-
Moccetti et al. 
(2008) 
(29) 
EFLA 943® 
Double blind, 
randomized, parallel 
 
144 subjects with 
stage 1 hypertension 
aged 25-60 years 
500 mg twice a 
day for 8 weeks 
Significant decrease in 
SBP and DBP, efficacy 
similar to Captopril 
Improvement of lipid 
profile 
Susalit et al. 
(2011)  
(28) 
ACE, Angiotensin-Converting Enzyme; BP, Blood Pressure; DBP, Diastolic BP; NO, Nitric Oxide; SBP, Systolic BP; SHR, Spontaneously 
Hypertensive Rats; SOD, Super Oxide Dismutase; VOO, Virgin Olive Oil; WR, Wistar Rats; WKR, Wistar Kyoto Rats  
 
Blood Pressure; DBP, Diastolic Blood Pressure; SBP, Systolic Blood Pressure; NO, Nitric Oxide; VOO, Virgin Olive Oil  
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6. CONTRIBUTIONS AND CONCLUSIONS 
Hypertension is a chronic disorder in which BP is elevated due to increased CO and 
altered PVR. The development of the disease is determined by genetic and 
environmental influences, being the latter modifiable risk factors. Thereby, before 
reaching advanced stages, hypertension can be prevented with lifestyle changes.  
Following this review, it has been proven that leaves, fruits and oil of Olea europaea L. 
contain phytochemicals capable of lowering BP. It is for that reason that olive oil and 
table olives could be considered putative functional foods in the prevention of 
hypertension in the future and nutritional recommendations could be made. However, 
stronger evidence is needed. 
Robust evidence has shown that VOO composition provides MUFAs and other minor 
compounds such as polyphenols, tocopherols, triterpenes, among others, which 
contribute to BP regulation and prevention of high BP levels. Thus, VOO intake should 
be recommended as the main the source of dietary fat replacing saturated fatty acids 
and polyunsaturated fatty acids in patients with borderline hypertension or already 
hypertensive. This is particularly important in individuals with MetS who, despite being 
at normal-high BP levels, suffer a sum of clinical alterations that greatly increase CVD 
risk. However, a limit consumption of VOO cannot be exceeded, as fatty acids contain 9 
kcal/g and, an increase of daily calorie intake, can lead to obesity and overfeeding.   
In general, table olives are restricted among hypertensive patients due to its sodium 
content, yet, olive fruits have high proportions of pentacyclic triterpenes and phenolic 
compounds of which cardioprotective activities have been described. Thus, their 
addition to the diet of hypertensive patients should be considered. Olive leaves contain 
bioactive compounds, particularly pentacyclic triterpenes and polyphenols in high 
concentrations. In preclinical and clinical studies, OLE has been shown to possess 
hypotensive activity with higher efficacy than lifestyle modifications. Therefore, olive 
leaves can be considered the main source for developing dietary supplements for 
individuals with hypertension.  
Regarding the bioactive compounds studied from Olea europaea L., all have shown 
beneficial effects on BP and cardiovascular health. Oleic acid has shown to be the chief 
responsible for the hypotensive effect of olive oil through molecular mechanisms in the 
lipid membrane. These data support recommendations to increase ingestion of MUFAs 
from VOO to avoid unfavourable BP levels.  
Among pentacyclic triterpenes evaluated, OA was the most effective in reducing BP, 
followed by ursolic acid and UV. OA has already been described as a potent hypotensive 
agent and its antihypertensive effects are correlated with natriuretic effect, reduction 
of aldosterone levels, vasodilation and modulation of oxidative status. Maslinic acid, 
despite being in smaller proportions, should be also attributed to the beneficial 
cardiovascular effects, according to Valero-Muñoz et al. (2014). Therefore, pentacyclic 
triterpenes clearly contribute to the overall antihypertensive effect of olive leaf extract 
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and may provide an inexpensive source to treat hypertension. Yet, the studies reviewed 
are performed pre-clinically, thus, additional studies in humans are needed.  
The health benefits of Olea europaea L. by-products are mostly due to their high 
polyphenol content. Hydroxytyrosol and oleuropein are the most important phenolic 
compounds in olive, which have proven an indisputable antioxidant and scavenging 
capacity against ROS. As Table 4 and Table 5 show, polyphenolic substances exert an 
antihypertensive activity thanks to the improvement of the pro-oxidative and pro-
inflammatory status, as well as of the endothelial function by enhancing the release of 
NO. These effects appear at both acute and long-term levels, and were observed in both 
genetically modified animal models and clinical trials in humans. In addition, 
polyphenols inhibit LDL oxidation, which gives them an additional cardioprotective 
effect in hypertensive subjects. On that account, phenolic compounds from Olea 
europaea L. as a dietary supplement to prevent hypertension deserve consideration. 
The ingestion of FVOO enriched with its own polyphenols should also be considered as 
a potential alternative to improve endothelial function in hypertensive patients.   
Besides, flavonoids have shown to modulate BP by increasing the production of NO and 
by ACE inhibition, which is the regulatory enzyme of RAAS and represents an important 
pharmacological target in the fight against hypertension. Yet, further investigation is 
required to analyse and interpret this mechanism of ACE inhibition.  
On the other hand, administration of OLE have provided a prophylactic effect against BP 
elevation in hypertensive animals in the reviewed investigations. In general, hypotensive 
effects of OLE have been greater in the high-dose treatment groups, with 1000 mg/day 
being the highest and showing comparable results with Captopril in its effective doses. 
Nevertheless, since this is a very high dose, the most effective dose to recommend for 
human administration is still unclear and more research is needed. Therefore, OLE has 
been proved to be safe and tolerable in hypertensive patients and represents a potential 
therapeutic tool in hypertension treatment.  
In conclusion, the hypotensive activity is provided by the combination of bioactive 
compounds fatty acids, polyphenols and pentacyclic triterpenes, which act 
synergistically but also isolated, involving various mechanisms related to the 
pathogenesis of hypertension. The present review, supports the traditional use of Olea 
europaea L. as antihypertensive agent and provide convincing evidence for the clinical 
use of its bioactive phytochemicals in the medicine of the future.  
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